Endo said the settlement includes no admission of wrongdoing by Endo or its subsidiaries.

Endo International has reportedly contacted a restructuring firm after thousands of opioid lawsuits.

Here are the biotech stocks to buy that we think will see magnified growth over the coming year. Real Money writer Bret Jensen reveals his top picks.

BioSpecifics, Front Yard Residential, Kaixin Auto Holdings, Trinseo and Centogene are some of Monday's top gainers.

BioSpecifics jumped on Monday after Endo International agreed to acquire the biopharma in a deal valued at about $540 million.

Alteryx, Group 1 Automotive, Endo International, Chromadex and Kiniksa Pharmaceuticals are some of Tuesday's top stock gainers.

Johnson & Johnson Faces New York State Insurance Fraud Action Linked to Opioid Crisis

Despite some downbeat stories and IPO overhang, Jim Cramer says, we're seeing the market rally thanks to the action in some great individual stocks.

Jim Cramer takes a look at Merck, Cloudflare, Exelon, Advanced Micro Devices, Endo Pharmaceuticals, Ionis Pharmaceuticals, Tandem Diabetes Care and more.

Home Depot closed out a busy week by naming CEO Ted Decker as chairman, unveiling a new $15 billion buyback and declaring a $1.90 per share dividend.

"Although we're confident in our ability to perform well in a range of market scenarios, we're mindful of the current macroeconomic trends," said CEO Gary Dickerson.

Deere's third quarter profits "reflected higher costs and production inefficiencies driven by the difficult supply-chain situation," said CEO John May.